Cat. No. 2500
Chemical Name: 3-[2-Cyano-3-(trifluoromethyl)pheno
Biological ActivityNovel CB1/CB2 receptor partial agonist (Ki values are 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively). Orally active CB1 agonist in vivo. Displays anti-hyperalgesic and antiallodynic properties in rat models of chronic neuropathic and inflammatory pain.
Licensing InformationSold for research purposes under agreement from Bayer
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
De Vry et al (2004) 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid CB1/CB2 receptor partial agonist with antihyperalgesic and antiallodynic effects. J.Pharmacol.Exp.Ther. 310 620. PMID: 15140913.
De Vry et al (2004) Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat. Eur J Pharmacol. 505 127. PMID: 15556145.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Bay 59-3074 include:
Ilatovskaya et al (2013) Pharmacological characterization of the P2 receptors profile in the podocytes of the freshly isolated rat glomeruli. Am J Physiol Cell Physiol 305 C1050. PMID: 24048730.
McGuinness et al (2009) Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter β-arrestin assay. Biol Psychiatry 14 49. PMID: 19171920.
Do you know of a great paper that uses Bay 59-3074 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Bay 59-3074, supplier, CB1/CB2, receptor, partial, agonists, cannabinoids, Non-Selective, Receptors, Bay59-3074, cb2r, cb1r, Tocris Bioscience, Non-selective Cannabinoid Agonist products
Find multiple products by catalog number
March 18 - 22, 2017
Little Rock, ARK, USA